Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...
Following positive results from the Phase 1 dose escalation study, BND-22 (SAR444881) is now being tested in Phase 2 trials as monotherapy for patients ...
The US Food and Drug Administration (FDA) has announced it has approved colon cancer drug ... Zaltrap, developed by Sanofi and Regeneron Pharmaceuticals, will compete with Roche Holding AG ...
Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...
GlobalData on MSN5d
Sanofi’s Sarclisa combo approved in Japan for newly diagnosed MMSanofi's Sarclisa (isatuximab) has gained approval from Japan’s MHLW for use in conjunction with VRd to treat newly diagnosed ...
The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...
Paris: Sanofi has announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in ...
Sanofi Oncology global head Olivier Nataf stated ... Sarclisa's non-proprietary name in the US is isatuximab-irfc, following US Food and Drug Administration guidance for the industry on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback